As such, the GLOW trial [14] is a phase III double-blind randomized global study that enrolled 507 CLDN18.2-positive (≥75% of tumor cells with moderate-to-strong CLDN18 membranous staining), HER2-negative, locally advanced unresectable, or metastatic gastric/gastroesophageal junction adenocarcinoma patients. The gene discussed is CLDN18; the disease is neoplasm.